CS Diagnostics Corp (CSDX)

[stocktowatch]

$CSDX on watch for news. stay tuned!!

[stocktowatch]

$CSDX " CS Group is advancing discussions with healthcare providers, facilities management companies, and distribution partners that cover North America, Europe, the Middle East, Africa, and Asia/Pacific to accelerate market entry and bring MEDUSA to global audiences. "

[stocktowatch]

$CSDX Chart

[stocktowatch]

$CSDX Need news imo..

[stocktowatch]

$CSDX Products - Elevate your hygiene standards instantly with MEDUSA’s powerful disinfection technology. Designed to provide immediate, long-lasting protection, Medusa transforms any space into a safe, germ-free environment you can trust. This isn’t just a disinfectant, it is your essential solution for a cleaner, safer today. https://medusa-sdp.com/en/

[The Night Stalker]

https://www.stockscores.com/charts/charts/?ticker=csdx

[toddski]

Does anyone think this company can actually make money?

[stocktowatch]

$CSDX 2025 First Quarter Report

https://otcmarkets.com/file/company/financial-report/465039/content

[stocktowatch]

$CSDX " CS Group is advancing discussions with healthcare providers, facilities management companies, and distribution partners that cover North America, Europe, the Middle East, Africa, and Asia/Pacific to accelerate market entry and bring MEDUSA to global audiences.

The surface disinfectant market is expected to grow from USD 5.46 Billion in 2023 to USD 8.84 Billion by 2030 driven by heightened awareness of infection prevention. CS Group's strategic valuation estimates MEDUSA can capture up to 3% market share by 2030 through focused B2B and retail channel expansion.

Thomas Fahrhöfer, President of the Board at CS Diagnostics Corp. mentioned:

"Where competitors sell volume through frequent reapplication, we deliver efficiency through lasting protection. This translates to real cost savings for facility managers and a superior value proposition in the market "

Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:

"MEDUSA requires reduced application frequency in high-traffic environments delivering cost and labour savings. With regulatory approvals progressing and a clear path to commercialization, we are confident that MEDUSA can capture meaningful market share while delivering value to our partners and end-users."

[stocktowatch]

$CSDX About MEDUSA MEDUSA (https://medusa-sdp.com/) is a Smart disinfectant Product designed to meet the highest standards of hygiene and safety. From rapid-acting Alcohol-based formulas to gentle Alcohol-free options, MEDUSA delivers robust protection, uncompromising efficacy, and eco-conscious formulas to safeguard your spaces.

Proven Effectiveness Against:

Bacteria: Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Enterococcus hirae

Fungi: Candida Albicans
Viruses: SARS-COV2, Covid families, Influenza families, and various Enveloped viruses

About CS Diagnostics Corp.

CS Diagnostic Corp. is a global healthcare innovation company committed to advancing medical diagnostics through innovation and precision technology. With a strong foundation in research and a global vision, the company delivers cutting-edge solutions to meet the evolving needs of the healthcare industry. https://finance.yahoo.com/news/cs-group-announces-valuation-medusa-140000101.html

[The Night Stalker]

https://www.stockscores.com/charts/charts/?ticker=agyp

[stocktowatch]

$CSDX Turning points,
https://www.barchart.com/stocks/quotes/CSDX/cheat-sheet

[jelaco]

Me too...lots of upside on this little gem

[MrVision68]

Lets get this rolling. I am buying

[The Night Stalker]

https://www.otcmarkets.com/stock/CSDX/security

[toddski]

The VP of the board "Mohammad EsSayed" says they are aiming to achieve $80 million in revenue in 2025 and $460 million in annual revenue within three years. Does anyone believe this at all?

[The Night Stalker]

https://www.stockscores.com/charts/charts/?ticker=csdx

[MrVision68]

I am new on this board because I bought 10K shares this morning. I am hoping to see good things from this stock

[The Night Stalker]

https://www.stockscores.com/charts/charts/?ticker=csdx

[stocktowatch]

Driving the Future of Healthcare $HIT, $OSRH, $THTX, $LPTX, $CSDX, Innovations in Health Insurance, Virtual Care, Oncology, and Chronic Disease Treatment https://www.marketscreener.com/quote/stock/HEALTH-IN-TECH-INC-180244227/news/Driving-the-Future-of-Healthcare-HIT-OSRH-THTX-LPTX-CSDX-Innovations-in-Health-Insurance-Virt-49449633/

[The Night Stalker]

https://www.stockscores.com/charts/charts/?ticker=csdx

[The Night Stalker]

https://www.stockscores.com/charts/charts/?ticker=csdx

[toddski]

This is an interesting company. I'm not sure it's cheap enough to buy yet, but has interesting prospects. 

[ANTI-BAGHOLDER]

You still in this?  Some of the DD seems interesting.  Obviously there is a seller in there right now. 

[ANTI-BAGHOLDER]

Bottom in?   9 million floater with plenty going on. 

[ANTI-BAGHOLDER]

Question is how low will it go??

[AveragePenny]

$CSDX CS Group Announces the Valuation of MEDUSA Surface Disinfectant at USD 513 Million

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cs-group-announces-the-valuation-of-medusa-surface-disinfectant-at-us-1018009

CHEYENNE, WY AND NEUSS, GERMANY / ACCESS Newswire / April 22, 2025 / CS Group announced the completion of a comprehensive valuation for its proprietary smart surface disinfectant, MEDUSA. The valuation conducted as of April 1, 2025 estimates the fair market value of these rights at USD 513 Million reflecting the significant growth potential and competitive advantages of the MEDUSA product line.

CS Group is advancing discussions with healthcare providers, facilities management companies, and distribution partners that cover North America, Europe, the Middle East, Africa, and Asia/Pacific to accelerate market entry and bring MEDUSA to global audiences.

The surface disinfectant market is expected to grow from USD 5.46 Billion in 2023 to USD 8.84 Billion by 2030 driven by heightened awareness of infection prevention. CS Group's strategic valuation estimates MEDUSA can capture up to 3% market share by 2030 through focused B2B and retail channel expansion.

Thomas Fahrhöfer, President of the Board at CS Diagnostics Corp. mentioned:

"Where competitors sell volume through frequent reapplication, we deliver efficiency through lasting protection. This translates to real cost savings for facility managers and a superior value proposition in the market "

Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:

"MEDUSA requires reduced application frequency in high-traffic environments delivering cost and labour savings. With regulatory approvals progressing and a clear path to commercialization, we are confident that MEDUSA can capture meaningful market share while delivering value to our partners and end-users."

[resx18]

CHEYENNE, WY AND NEUSS, GERMANY / ACCESS Newswire / April 22, 2025 / CS Group announced the completion of a comprehensive valuation for its proprietary smart surface disinfectant, MEDUSA. The valuation conducted as of April 1, 2025 estimates the fair market value of these rights at USD 513 Million reflecting the significant growth potential and competitive advantages of the MEDUSA product line.

CS Group is advancing discussions with healthcare providers, facilities management companies, and distribution partners that cover North America, Europe, the Middle East, Africa, and Asia/Pacific to accelerate market entry and bring MEDUSA to global audiences.

The surface disinfectant market is expected to grow from USD 5.46 Billion in 2023 to USD 8.84 Billion by 2030 driven by heightened awareness of infection prevention. CS Group's strategic valuation estimates MEDUSA can capture up to 3% market share by 2030 through focused B2B and retail channel expansion.

Thomas Fahrhöfer, President of the Board at CS Diagnostics Corp. mentioned:

"Where competitors sell volume through frequent reapplication, we deliver efficiency through lasting protection. This translates to real cost savings for facility managers and a superior value proposition in the market "

Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:

"MEDUSA requires reduced application frequency in high-traffic environments delivering cost and labour savings. With regulatory approvals progressing and a clear path to commercialization, we are confident that MEDUSA can capture meaningful market share while delivering value to our partners and end-users."

[stocktowatch]

$CSDX " The proposed financing outlined in a Letter of Intent issued by Carlos Arturo Marcucci Caceres, legal representative of SAN ART CAPITAL SAS in return of Series C Preferred Stock of CS Diagnostics Corp. (OTCQB:CSDX). The strategic funding arrangement is intended to strengthen CS Diagnostics Corp.'s operational capabilities, drive growth, and scale its products CS - Protect Hydrogel and MEDUSA in global markets. "

[stocktowatch]

$CSDX Good looking chart must see


Weekly

[stocktowatch]

$CSDX to announce that it has received a Letter of Intent from SAN ART CAPITAL SAS, a leading advisory and investment management firm based in Bogotá, Colombia for a proposed USD 5,000,000 (five million US dollars) equity loan to support the production and commercialization of CS Diagnostic Corp.'s assets and strategic developments.


https://finance.yahoo.com/news/cs-diagnostics-corp-entering-5-133500626.html

[AveragePenny]

$CSDX CS Diagnostics Corp. is Entering into a $5 Million Loan Agreement with SAN ART CAPITAL SAS

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cs-diagnostics-corp-is-entering-into-a-5-million-loan-agreement-with-1014921

CHEYENNE, WY / ACCESS Newswire / April 15, 2025 / Neuss, Germany: CS Diagnostics Corp. is pleased to announce that it has received a Letter of Intent from SAN ART CAPITAL SAS, a leading advisory and investment management firm based in Bogotá, Colombia for a proposed USD 5,000,000 (five million US dollars) equity loan to support the production and commercialization of CS Diagnostic Corp.'s assets and strategic developments.

The proposed financing outlined in a Letter of Intent issued by Carlos Arturo Marcucci Caceres, legal representative of SAN ART CAPITAL SAS in return of Series C Preferred Stock of CS Diagnostics Corp. (OTCQB:CSDX). The strategic funding arrangement is intended to strengthen CS Diagnostics Corp.'s operational capabilities, drive growth, and scale its products CS - Protect Hydrogel and MEDUSA in global markets.

Strategic Purpose:

The intended use of funds will be allocated to support the commercial rollout of CS- Protect Hydrogel further R&D, operational expansions, and U.S. EPA approval for its Smart Disinfectant Product MEDUSA. The parties will proceed with final due diligence and definitive agreement negotiations with the goal of closing the transaction in the coming weeks.

Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:

"This funding agreement will mark a significant milestone in strengthening our financial foundation and aligning with a strategic financial capability. It will allow us to confidently advance through key regulatory stages and operates in several markets while preserving shareholder value and minimizing dilution."

[resx18]

CHEYENNE, WY / ACCESS Newswire / April 15, 2025 / Neuss, Germany: CS Diagnostics Corp. is pleased to announce that it has received a Letter of Intent from SAN ART CAPITAL SAS, a leading advisory and investment management firm based in Bogotá, Colombia for a proposed USD 5,000,000 (five million US dollars) equity loan to support the production and commercialization of CS Diagnostic Corp.'s assets and strategic developments.

The proposed financing outlined in a Letter of Intent issued by Carlos Arturo Marcucci Caceres, legal representative of SAN ART CAPITAL SAS in return of Series C Preferred Stock of CS Diagnostics Corp. (OTCQB:CSDX). The strategic funding arrangement is intended to strengthen CS Diagnostics Corp.'s operational capabilities, drive growth, and scale its products CS - Protect Hydrogel and MEDUSA in global markets.

Strategic Purpose:

The intended use of funds will be allocated to support the commercial rollout of CS- Protect Hydrogel further R&D, operational expansions, and U.S. EPA approval for its Smart Disinfectant Product MEDUSA. The parties will proceed with final due diligence and definitive agreement negotiations with the goal of closing the transaction in the coming weeks.

Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:

"This funding agreement will mark a significant milestone in strengthening our financial foundation and aligning with a strategic financial capability. It will allow us to confidently advance through key regulatory stages and operates in several markets while preserving shareholder value and minimizing dilution."

[resx18]

$CSDX is Entering into a $5 Million Loan Agreement with SAN ART CAPITAL SAS
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cs-diagnostics-corp-is-entering-into-a-5-million-loan-agreement-with-1014921

[resx18]

CS Diagnostics Corp. @CSDX_CSDCorp
17m
Our Annual Report for the period ending Dec 31, 2024 has been amended to reflect the inclusion of new PCAOB auditors with consent.
Read here: https://shorturl.at/sXSiw
$CSDX

[resx18]

Good Morning $CSDX

[resx18]

Got a few more

[Brocool]

CS Diagnostics Corp.'s global presence is enhanced by strategic collaborations with healthcare sectors globally, ensuring that our comprehensive services and solutions are available in multiple countries.$CSDX

[Brocool]

CS Diagnostics Corp. serves a varied international market and specializes at traversing complicated regulatory landscapes to gain product approval and distribution.$CSDX

[Brocool]

CS Diagnostics Corp.'s team of experienced professionals works closely with top universities and experts to ensure we remain at the forefront of medical technology.$CSDX

[Brocool]

CS Diagnostics Corp.'s flagship product, CS Protect Hydrogel is a pioneering advancement of medical innovation.$CSDX

[Brocool]

CS Diagnostics Corp. a renowned member of the CS Group, is a medical sector leader committed to advancing patient care through innovative solutions.$CSDX

[resx18]

MEDUSA is completely safe around pets! It's gentle and alcohol-free formula effectively disinfects all surfaces your pets come into contact with including toys, carriers, grooming tools, kennels, and resting spaces without leaving harmful residues. @MedusaSdp's advanced hygiene… pic.twitter.com/z3TbsOJKOH

— CS Diagnostics Corp. (@CSDX_CSDCorp) April 11, 2025

[resx18]

Real company on the OTC. 👀

[Brocool]

With a focus on quality and a strong range of solutions, CS Diagnostics Corp. is well-positioned to change the future of healthcare by delivering on our promise of greater health through better technology.$CSDX

[Brocool]

CS Diagnostics Corp. serves a varied international market and specializes at traversing complicated regulatory landscapes to gain product approval and distribution.$CSDX

[Brocool]

CS Diagnostics Inc.'s flagship product, CS Protect Hydrogel is a pioneering advancement of medical innovation.$CSDX

[Brocool]

With decades of experience in designing, manufacturing, and selling wellness and medical products, CS Diagnostics Inc. have established themselves as a reliable partner in global healthcare. $CSDX

[Brocool]

CS Diagnostics Corp. a renowned member of the CS Group, is a medical sector leader committed to advancing patient care through innovative solutions.$CSDX

[resx18]

The next update will send this flying!!